Search Result

Results for "

LSTA1

" in MedChemExpress (MCE) Product Catalog:

標的別:	Complement System (3) Integrin (3) Isotope-Labeled Compounds (2)
研究分野別:	Cancer (3)

阻害剤およびアゴニスト

ペプチド

同位体標識化合物

製品番号	製品名	Target	研究分野	構造式

HY-P3448

Certepetide CEND-1; iRGD; LSTA1	Integrin Complement System	Cancer
Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating *NRP-1*, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors ^[1] .

HY-P3448S

Certepetide-13C6,15N2 CEND-1-¹³C₆,¹⁵N₂; iRGD-¹³C₆,¹⁵N₂; LSTA1-¹³C₆,¹⁵N₂	Isotope-Labeled Compounds Complement System Integrin	Cancer
Certepetide- ¹³C₆, ¹⁵N₂ (CEND-1- ¹³C₆, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating *NRP-1*, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors ^[1] .

HY-P3448S1

Certepetide-13C2,15N CEND-1-¹³C₂,¹⁵N; iRGD-¹³C₂,¹⁵N; LSTA1-¹³C₂,¹⁵N	Isotope-Labeled Compounds Complement System Integrin	Cancer
Certepetide- ¹³C₂, ¹⁵N (CEND-1- ¹³C₂, ¹⁵N) is the ¹³C- and ¹⁵N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating *NRP-1*, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors ^[1] .

製品番号	製品名	Target	研究分野

HY-P3448

Certepetide CEND-1; iRGD; LSTA1	Integrin Complement System	Cancer
Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating *NRP-1*, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors ^[1] .

HY-P3448S

Certepetide-13C6,15N2 CEND-1-¹³C₆,¹⁵N₂; iRGD-¹³C₆,¹⁵N₂; LSTA1-¹³C₆,¹⁵N₂	Isotope-Labeled Compounds Complement System Integrin	Cancer
Certepetide- ¹³C₆, ¹⁵N₂ (CEND-1- ¹³C₆, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating *NRP-1*, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors ^[1] .

HY-P3448S1

Certepetide-13C2,15N CEND-1-¹³C₂,¹⁵N; iRGD-¹³C₂,¹⁵N; LSTA1-¹³C₂,¹⁵N	Isotope-Labeled Compounds Complement System Integrin	Cancer
Certepetide- ¹³C₂, ¹⁵N (CEND-1- ¹³C₂, ¹⁵N) is the ¹³C- and ¹⁵N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating *NRP-1*, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors ^[1] .

製品番号	製品名	構造式

HY-P3448S

Certepetide-13C6,15N2
Certepetide- ¹³C₆, ¹⁵N₂ (CEND-1- ¹³C₆, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating *NRP-1*, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors ^[1] .

Certepetide-13C6,15N2

Certepetide- ¹³C₆, ¹⁵N₂ (CEND-1- ¹³C₆, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors ^[1] .

HY-P3448S1

Certepetide-13C2,15N
Certepetide- ¹³C₂, ¹⁵N (CEND-1- ¹³C₂, ¹⁵N) is the ¹³C- and ¹⁵N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating *NRP-1*, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors ^[1] .

Certepetide-13C2,15N

Certepetide- ¹³C₂, ¹⁵N (CEND-1- ¹³C₂, ¹⁵N) is the ¹³C- and ¹⁵N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors ^[1] .

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

お名前
メール *

	Sorry, but the email address you supplied was invalid.